(lp0
S'Griffin Lifts Price Target on ZIOPHARM Oncology Inc.  Ahead of ... Smarter Analyst - Feb 9, 2017 Griffin analyst Keith Markey sees golden prospects ahead for ZIOPHARM Oncology Inc. , particularly taking into account the seven clinical trials the firm has forthcoming on the table for this year; trials which the analyst commends as&nbsp;...ZIOPHARM Oncology, Inc.  added about 7.4 percent in value since last ... - The Independent Republic'
p1
aS"The Reason Behind ZIOPHARM Oncology Inc.'s 11% Gain Motley Fool - Nov 10, 2016 Shares of ZIOPHARM Oncology , a clinical-stage biopharmaceutical company focused on the development of various immunotherapeutic cancer treatments, surged as much as 11% during Thursday's trading session after the company&nbsp;...Stock Update : ZIOPHARM Oncology Inc. Reports Third Quarter 2016 ... - Smarter Analyst"
p2
aS"Better Buy: Ziopharm Oncology, Inc. vs. Juno Therapeutics Motley Fool - Nov 3, 2016 And although it hasn't been as closely associated with CAR-T as Juno Therapeutics, Ziopharm Oncology  is part of a collection of entities  developing a therapeutic pipeline in the same class,&nbsp;...ZIOPHARM Announces Four Presentations at the 2016 ASH Annual Meeting - GlobeNewswire "
p3
aS"Better Buy: Ziopharm Oncology, Inc. vs. Intrexon Corporation Motley Fool - Oct 14, 2016 The close relationship between Ziopharm Oncology  and Intrexon  hasn't gone unnoticed by investors -- in fact, it's impossible to overlook since the latter is likely responsible for a majority of the former's $660 million market cap."
p4
aS'Griffin Commends ZIOPHARM Oncology Inc.  Following Suspension Of Breast ... Smarter Analyst - Feb 27, 2017 ZIOPHARM Oncology Inc.  has indicating the firm will be shifting its R&amp;D pipeline, centering its IL-12 gene therapy program on glioblastoma following the suspension of future development of its breast cancer therapy program.Shares of ZIOPHARM Oncology Inc  Plunge -11.08% - Energy IndexZIOPHARM Oncology Inc  Rating Lowered to Sell at Zacks Investment Research - Sports Perspectives'
p5
aS"Company Update : ZIOPHARM Oncology Inc. Announces 4Q:16 Financial ... Smarter Analyst - Feb 16, 2017 ZIOPHARM Oncology Inc.  announced financial results for the fourth quarter ended December 31, 2016, and provided an update on the Company's recent activities.Two Stocks in Focus: Pulmatrix, Inc. , ZIOPHARM Oncology, Inc ... - The Newburgh PressZIOPHARM Reports Fourth-Quarter 2016 Financial Results and Provides Update on ... - GlobeNewswire "
p6
aS'Company Update : ZIOPHARM Oncology Inc. And Intrexon Corp To ... Smarter Analyst - Jan 10, 2017 ZIOPHARM Oncology Inc.  and Intrexon Corp  announced the signing of a Cooperative Research and Development Agreement  with the National Cancer Institute  for the development of adoptive cell transfer&nbsp;...'
p7
aS'ZIOPHARM Oncology Inc  Moves Higher on Volume Spike for March 10 Equities.com - Mar 10, 2017 ZIOPHARM Oncology Inc  traded on unusually high volume on Mar. 10, as the stock gained 7.82% to close at $6.89. On the day, ZIOPHARM Oncology Inc saw 1.97 million shares trade hands on 8,502 trades. Considering that the stock averages only a&nbsp;...Which insiders are trading ZIOPHARM Oncology, Inc. ? - Post Analyst'
p8
aS'Better Buy: Ziopharm Oncology, Inc. vs. Celgene Motley Fool - Jun 18, 2016 One of the coolest kids on the T-cell block to receive a market beatdown was clinical-stage Ziopharm Oncology, Inc. .'
p9
aS'Better Buy: Ziopharm Oncology, Inc. vs. Alnylam Pharmaceuticals, Inc. Motley Fool - Sep 24, 2016 Clinical-stage biotechs Ziopharm Oncology  and Alnylam Pharmaceuticals , for example, have both suffered in 2016.'
p10
a.